Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KINE-501B
- Development stage
- Preclinical
- Lead developer
- Kine Sciences
- Modality
- Peptides
01
Overview
KINE-501B is a peptide-based therapeutic candidate currently in the discovery stage, developed by Kine Science for the treatment of Frontotemporal Dementia (FTD). The drug is designed to modulate the activity of microglial cells, which are the resident immune cells of the central nervous system. In neurodegenerative conditions like FTD, dysfunctional microglial activation contributes to chronic neuroinflammation and the progression of neuronal damage. KINE-501B aims to regulate these microglial responses to provide neuroprotective effects and potentially slow the cognitive and functional decline associated with the disease.
Beyond the preview
Go deeper on KINE-501B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KINE-501B.